China Business Intelligence Network News: Breast cancer is the most common cancer among female cancer patients, and the number of new breast cancer patients in China is increasing year by year. According to Frost & Sullivan data, breast cancer has become the world's largest new cancer in 2020.
The incidence of breast cancer is often genetically related, and the incidence is higher in women aged 40 to 60 years, around menopause, usually in the epithelial tissue of the breast glands. Early manifestations are small, single, painless, progressively growing lumps in the affected milk, which develop into late stages, where the superficial skin is invaded, induration of the skin may occur, and even skin ulcers may form.
First, the global market
According to Frost & Sullivan, the global prevalence of breast cancer is on the rise year by year. The number of new breast cancer patients worldwide increased from 2 million in 2016 to 2.26 million in 2020, with a COMPOUND ANNUAL GROWTH rate of 3.1% during the period. It is expected to reach 2.47 million people in 2025 and maintain steady growth.
Data source: Frost & Sullivan, compiled by the China Commercial Industry Research Institute
The national comprehensive cancer network (NCCN) website published the first edition of the 2021 clinical practice guidelines for breast cancer, the National Comprehensive Cancer Network (NCCN) Breast Cancer Clinical Practice Guidelines (2021 edition), which clearly targets endocrine therapy for patients who are estrogen receptor (ER)-positive, as shown in the following table:
Source: National Comprehensive Cancer Network (NCCN) Breast Cancer Clinical Practice Guidelines (2021 edition), compiled by the China Commercial Industry Research Institute
Due to the rising incidence of breast cancer worldwide and the increasing number of treatment options, the global breast cancer drug market grew from $21.5 billion in 2016 to $31.8 billion in 2020, with a compound annual growth rate of 10.3%. The global breast cancer drug market is expected to reach $47.5 billion by 2025.
Second, the Chinese market
According to data released by the National Cancer Center, the number of new breast cancer patients in China has increased from 310,000 in 2016 to 330,000 in 2020. With the implementation of early diagnosis and early screening of breast cancer, it is expected that the number of new breast cancer patients will continue to increase in the future, and it is expected to reach 360,000 in 2025.
According to the "Chinese Breast Cancer Diagnosis and Treatment Guidelines" issued by the Chinese Anti-Cancer Association in 2020, breast cancer can be treated according to molecular classification for postoperative drug treatment. The 2021 National Breast Cancer Conference and the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Annual Meeting issued the "Chinese Clinical Oncology Association (CSCO) Breast Cancer Diagnosis and Treatment Guidelines (2021 Edition)", which clearly states that endocrine therapy should be used for estrogen receptor (ER)-positive patients, and the specific stratification is shown in the following table:
Source: China Breast Cancer Diagnosis and Treatment Guidelines, compiled by China Commercial Industry Research Institute
With the successive approval of targeted therapeutic drugs in China and their entry into the national medical insurance catalogue, the size of China's breast cancer drug market has shown a rapid growth trend, from 30 billion yuan in 2016 to 50.7 billion yuan in 2020, with a compound annual growth rate of 14.0%. China's breast cancer market is expected to grow to 81.8 billion yuan in 2025 at a higher growth rate than the world.
For more information, please refer to the "Research Report on Market Prospects and Investment Opportunities in China's Pharmaceutical Industry" issued by the China Commercial Industry Research Institute, and the China Commercial Industry Research Institute also provides industrial big data, industrial intelligence, industrial research reports, industrial planning, park planning, 14th Five-Year Plan, industrial investment attraction and other services.